

IN THE UNITED STATES PATENT & TRADEMARK OFFICEApplicant: KUMAR *et al.*

Serial No.: 10/541,140 Examiner: Morris, Patricia L.

Filing Date: 06/30/2005 Group Art Unit: 1625

For: MAGNESIUM SALT OF IMIDAZOLE DERIVATIVE

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT MAILED
MARCH 13, 2007

Dear Ms. Morris,

In response to the Office Action dated March 13, 2007, Applicants elect Group I without traverse as defined by Examiner. The claims have been amended accordingly by the Applicant. Claims 29-50 represent subject matter of Group I only, construed according to 37CFR1.475(b) subparagraph 3, as suggested by the Examiner. The Examiner is therefore requested to examine these claims immediately.

Authorization is hereby given to charge any fees deemed to be due in connection with this Response to Deposit Account No. 50-0912.

The Applicant reserves the right to pursue subject matter reflected in, for example, the cancelled claims in future applications.

Respectfully submitted,

KUMAR *et al.*

By:


George E. Heibel
Reg. No. 42,648

Date: April 12, 2007

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5334
Fax: (609) 514-9779